An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03285906
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

  • Esophageal Gastric Cardia Type Metaplasia
  • Esophagus Cancer, Stage III
  • Esophagus Cancer, Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Targeted therapy Apatinib：500 mg，po，qd

Study Details

The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib（500mg/d）for the second - line treatment of esophageal cancer or esophageal and gastric

Key Dates

Start date
Mar 1, 2017
Status verified
Jul 2017
Primary completion
Jun 30, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Experimental: Treatment group
    Apatinib：500 mg，po，qd

Primary Outcome Measure

progression-free survival [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

Related Studies